knowledge -WSS

knowledge

author：leisure time 2025-09-28 15:55:32 - browse：21888

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Scrutiny of post

focus

WSS

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Scrutiny of post

Cue Health, Covid

Liver decline slowed by off

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Newly revealed memo details efforts to keep Trump in power following election loss

explore

knowledge

hotspot

Psychedelics group wrestles with new pharma identity

Making the case for fair compensation in clinical trials

Medical records are filled with copy

Where are patients getting their prescriptions for GLP

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Trump, Nauta plead not guilty to new classified docs charges but De Oliveira still not arraigned

Tori Bowie and the unacceptable rates of Black maternal death

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

focus

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

H5N1 virus can be tracked in retail milk, scientists say

FDA poised to publish guidelines for clinical trial diversity

Newly revealed memo details efforts to keep Trump in power following election loss

Liver decline slowed by off

knowledge

entertainment

focus

Wikipedia